Cargando…

Glibenclamide Administration Attenuates Infarct Volume, Hemispheric Swelling, and Functional Impairments following Permanent Focal Cerebral Ischemia in Rats

Studies from a single laboratory have shown that in rodent models of permanent stroke, administration of the sulfonylurea glibenclamide (Glib) is highly effective in reducing edema, mortality, and lesion volume. The Stroke Therapy Academic Industry Roundtable (STAIR) recommends that new acute treatm...

Descripción completa

Detalles Bibliográficos
Autores principales: Wali, Bushra, Ishrat, Tauheed, Atif, Fahim, Hua, Fang, Stein, Donald G., Sayeed, Iqbal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3440943/
https://www.ncbi.nlm.nih.gov/pubmed/22988544
http://dx.doi.org/10.1155/2012/460909
_version_ 1782243213577289728
author Wali, Bushra
Ishrat, Tauheed
Atif, Fahim
Hua, Fang
Stein, Donald G.
Sayeed, Iqbal
author_facet Wali, Bushra
Ishrat, Tauheed
Atif, Fahim
Hua, Fang
Stein, Donald G.
Sayeed, Iqbal
author_sort Wali, Bushra
collection PubMed
description Studies from a single laboratory have shown that in rodent models of permanent stroke, administration of the sulfonylurea glibenclamide (Glib) is highly effective in reducing edema, mortality, and lesion volume. The Stroke Therapy Academic Industry Roundtable (STAIR) recommends that new acute treatments for ischemic stroke to be replicated across different laboratories. Accordingly, we examined the effect of low-dose Glib in a permanent suture occlusion model of stroke. Male Sprague-Dawley rats underwent permanent middle cerebral artery occlusion (pMCAO) followed by an initial intraperitoneal injection of Glib (10 μg/kg) and the start of a constant infusion (200 ng/h) via miniosmotic pump at the onset of ischemia. Functional deficits were assessed by Neurological Severity Score (NSS) and grip-strength meter at 24 and 48 h after pMCAO. Glib-treated rats showed a significant reduction in infarct volume, lower NSS, and less hemispheric swelling compared to vehicle. Grip strength was decreased significantly in pMCAO rats compared to shams and significantly improved by treatment with Glib. Taken together, these data indicate that Glib has strong neuroprotective effects following ischemic stroke and may warrant further testing in future clinical trials for human stroke.
format Online
Article
Text
id pubmed-3440943
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-34409432012-09-17 Glibenclamide Administration Attenuates Infarct Volume, Hemispheric Swelling, and Functional Impairments following Permanent Focal Cerebral Ischemia in Rats Wali, Bushra Ishrat, Tauheed Atif, Fahim Hua, Fang Stein, Donald G. Sayeed, Iqbal Stroke Res Treat Research Article Studies from a single laboratory have shown that in rodent models of permanent stroke, administration of the sulfonylurea glibenclamide (Glib) is highly effective in reducing edema, mortality, and lesion volume. The Stroke Therapy Academic Industry Roundtable (STAIR) recommends that new acute treatments for ischemic stroke to be replicated across different laboratories. Accordingly, we examined the effect of low-dose Glib in a permanent suture occlusion model of stroke. Male Sprague-Dawley rats underwent permanent middle cerebral artery occlusion (pMCAO) followed by an initial intraperitoneal injection of Glib (10 μg/kg) and the start of a constant infusion (200 ng/h) via miniosmotic pump at the onset of ischemia. Functional deficits were assessed by Neurological Severity Score (NSS) and grip-strength meter at 24 and 48 h after pMCAO. Glib-treated rats showed a significant reduction in infarct volume, lower NSS, and less hemispheric swelling compared to vehicle. Grip strength was decreased significantly in pMCAO rats compared to shams and significantly improved by treatment with Glib. Taken together, these data indicate that Glib has strong neuroprotective effects following ischemic stroke and may warrant further testing in future clinical trials for human stroke. Hindawi Publishing Corporation 2012 2012-09-04 /pmc/articles/PMC3440943/ /pubmed/22988544 http://dx.doi.org/10.1155/2012/460909 Text en Copyright © 2012 Bushra Wali et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Wali, Bushra
Ishrat, Tauheed
Atif, Fahim
Hua, Fang
Stein, Donald G.
Sayeed, Iqbal
Glibenclamide Administration Attenuates Infarct Volume, Hemispheric Swelling, and Functional Impairments following Permanent Focal Cerebral Ischemia in Rats
title Glibenclamide Administration Attenuates Infarct Volume, Hemispheric Swelling, and Functional Impairments following Permanent Focal Cerebral Ischemia in Rats
title_full Glibenclamide Administration Attenuates Infarct Volume, Hemispheric Swelling, and Functional Impairments following Permanent Focal Cerebral Ischemia in Rats
title_fullStr Glibenclamide Administration Attenuates Infarct Volume, Hemispheric Swelling, and Functional Impairments following Permanent Focal Cerebral Ischemia in Rats
title_full_unstemmed Glibenclamide Administration Attenuates Infarct Volume, Hemispheric Swelling, and Functional Impairments following Permanent Focal Cerebral Ischemia in Rats
title_short Glibenclamide Administration Attenuates Infarct Volume, Hemispheric Swelling, and Functional Impairments following Permanent Focal Cerebral Ischemia in Rats
title_sort glibenclamide administration attenuates infarct volume, hemispheric swelling, and functional impairments following permanent focal cerebral ischemia in rats
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3440943/
https://www.ncbi.nlm.nih.gov/pubmed/22988544
http://dx.doi.org/10.1155/2012/460909
work_keys_str_mv AT walibushra glibenclamideadministrationattenuatesinfarctvolumehemisphericswellingandfunctionalimpairmentsfollowingpermanentfocalcerebralischemiainrats
AT ishrattauheed glibenclamideadministrationattenuatesinfarctvolumehemisphericswellingandfunctionalimpairmentsfollowingpermanentfocalcerebralischemiainrats
AT atiffahim glibenclamideadministrationattenuatesinfarctvolumehemisphericswellingandfunctionalimpairmentsfollowingpermanentfocalcerebralischemiainrats
AT huafang glibenclamideadministrationattenuatesinfarctvolumehemisphericswellingandfunctionalimpairmentsfollowingpermanentfocalcerebralischemiainrats
AT steindonaldg glibenclamideadministrationattenuatesinfarctvolumehemisphericswellingandfunctionalimpairmentsfollowingpermanentfocalcerebralischemiainrats
AT sayeediqbal glibenclamideadministrationattenuatesinfarctvolumehemisphericswellingandfunctionalimpairmentsfollowingpermanentfocalcerebralischemiainrats